M-T2: A poxvirus TNF receptor homologue with dual activities

Immunology and Cell Biology

Volumn 74, Issue 6, 1996, Pages 538-545

  Sedger, Lisa ^a   McFadden, Grant ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

apoptosis; immune modifiers; poxvirus; TNF; TNF receptor superfamily

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; POXVIRUS; REVIEW; VIRULENCE;

POXVIRIDAE;

EID: 0029772017     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1996.87     Document Type: Review

References (77)

1. Marrack P, Kappler J. Subversion of the immune system by pathogens. Cell 1994; 78: 323-32.
2. McFadden G. Viroceptors, Virokines and Related Immune Modulators Encoded by DNA Viruses. Austin: RG Landes Co., 1995.
3. Spriggs M. One step ahead of the game: Viral immunomodulatory molecules. Annu. Rev. Immunol. 1996; 14: 101-30.
4. Moss B. Poxviridac and their replication. In: Fields NB, Knipe DM, eds. Virology. New York: Raven Press, 1990; 2079-2111.
5. Moss B. Regulation of Vaccinia virus transcription. Ann. Rev. Biochem. 1990; 59: 661-88.
6. Smith G. Vaccinia virus glycoproteins and immune evasion. J. Gen. Virol. 1993; 74: 1725-40.
7. Pickup DJ. Poxviral modifiers of cytokine responses to infection. Infect. Agents Dis. 1994; 3: 116-27.
8. McFadden G, Graham K, Ellison K et al. Interruption of cytokine networks by poxviruses: Lessons from myxoma virus. J. Leuk. Biol. 1995; 57: 731-8.
9. Smith G, Chan YS. Two Vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J. Gen. Virol. 1991; 72: 511-18.
10. Spriggs M, Hruby DE, Maliszewski CR et al. Vaccinia and Cowpox viruses encode a novel secreted Interleukin-1-binding protein. Cell 1992; 71: 145-52.
11. Alcamai A, Smith G. A soluble receptor for interleukin-1β encoded by Vaccinia virus: A novel mechanism of virus modulation of the host response to infection. Cell 1992; 71: 153-67.
12. Upton C, Mossman K, McFadden G. Encoding of a homologue of the IFN-γ receptor by myxoma virus. Science 1992; 258: 1369-72.
13. Symonds JA, Alcami A, Smith G. Vaccinia virus encoded a soluble type I interferon receptor of novel structure and broad species specificity. Cell 1995; 81: 551-60.
14. Twardzik DR, Brown JP, Ranchalis JE, Tolaro GJ, Moss B. Vaccinia virus infected cells release a novel polypeptide functionally related to transforming and epidermal growth factors. Proc. Natl Acad. Sci. USA 1985; 82: 5300-4.
15. King CS, Cooper JA, Moss B, Twardzik DR. Vaccinia virus growth factor stimulates tryosine protein kinase activity of A431 cell epidermal growth factor receptors. Mol. Cell. Biol. 1986; 6: 332-6.
16. Opgenorth A, Graham K, Nation N, Strayer D, McFadden G. Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor. J. Virol. 1992; 66: 4720-31.
17. Lyttle DJ, Fraser KM, Fleming SB, Mercer AA, Robinson AJ. Homologues of vascular endothelial growth factor are encoded by the poxvirus orf virus. J. Virol. 1994; 68: 84-92.
18. Pickup DJ, Ink BS, Hu W, Ray CA, Joklil WK. Hemorrhage in lesions caused by cowpox virus is induced by a viral protein that is related to plasma protein inhibitors by serine proteases. Proc. Natl Acad. Sci. USA 1986; 83: 7698-702.
19. Ray CA, Black RA, Kronheim SR et al. Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme. Cell 1992; 69: 597-604.
20. Terawi M, Dixit VM. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus CrmA gene product. J. Biol. Chem. 1995; 270: 3255-60.
21. Ali AN, Turner PC, Brooks MA, Moyer RA. The SPI-1 gene of rabbitpox virus determines host range and is required for hemorrhagic pock formation. Virology 1994; 202: 305-314.
22. Turner P, Musy PY, Moyer RW. Poxvirus Serpins. In: McFadden G, (ed.) Viroceptors, Virokines and Related Immune Modulators Encoded by DNA Viruses. Austin: RG Landes Co., 1995; 67-88.
23. Macen JL, Upton C, Nation N, McFadden G. SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology 1993; 195: 348-63.
24. Beattie E, Tartaglia J, Paoletti E. Vaccinia virus-encoded eIF-2a homologue abrogates the antiviral effect of interferon. Virology 1991; 183: 419-22.
25. Chang H-W, Watson JC, Jacobs BL. The E3L gene of Vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc. Natl Acad. Sci. USA 1992; 89: 4825.
26. Davies MV, Elroy-Stein O, Jagus R, Moss B, Kaufman RJ. The Vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2. J. Virol. 1992; 66: 1943-50.
27. Davies MV, Chang H-W, Jacobs BL, Kafman RJ. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J. Virol. 1993; 67: 1688-92.
28. Russell RJ, Robbins SJ. Cloning and molecular characterisation of the myxoma virus genome. Virology 1989; 170: 147-59.
29. Macaulay C, Upton C, McFadden G. Tumorigenic poxviruses: Transcriptional mapping of the inverted repeats of Shope fibroma virus. Virology 1987; 158: 381-93.
30. Upton C, DeLange AM, McFadden G. Tumorigenic poxviruses: Genomic organisation and DNA sequence of the telomeric region of the shope fibroma virus genome. Virology 1987; 160: 20-30.
31. Loetscher H, Pan YE, Lahm H-W et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990; 61: 351-9.
32. Schall T, Lewis M, Koller K et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990; 61: 361-70.
33. Smith C, Davis T, Anderson D et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019-23.
34. Upton C, Macen JL, Schreiber M, McFadden G. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. Virology 1991; 184: 370-81.
35. Hu F-Q, Chan YS, Pickup DJ. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology 1994; 204: 343-56.
36. Smith CA, Goodwin RG. Tumor necrosis factor receptors in the poxvirus family: Biological and genetic implications. In: McFadden G (ed.) Viroceptors, Virokines and Related Immune Modulators Encoded by DNA Viruses. Austin: RG. Landes Co., 1995; 29-40.
37. Shchelkunov SN, Blinov VM, Sandakhchiev, LS. Genes of Variola and vaccinia viruses necessary to overcome the host protective mechanisms. FEBS Lett. 1993; 319: 80-3.
38. Massung RF, Esposito JJ, Liu L-I et al. Potential virulence determinants in terminal regions of variola smallpox virus genome. Nature 1993; 366: 748-51.
39. Massung RF, Li L-I, Qi J et al. Analysis of the complete genome of smallpox variola major sirus strain Bangladesh-1975. Virology 1994; 201: 215-40.
40. Goebel SJ, Johnson G, Perkus Davis J, Winslow J, Paoletti E. The complete DNA sequence of Vaccinia virus. Virology 1990; 179: 247-66.
41. Howard S, Chan YS, Smith G. Vaccinia virus homologues of the Shope Fibroma Virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family. Virology 1991; 180: 633-47.
42. Bazan JF. Emerging families of cytokines and receptors. Curr. Biol. 1993; 3: 6-10.
43. Armitage R. Tumor necrosis factor receptor superfamily members and their ligands. Curr. Opin. Immunol. 1994; 6: 407-13.
44. Smith CA, Farrah T, Goodwin R. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 1994; 76: 959-62.
45. Peitsch M, Tschopp J. Comparative molecular modelling of the fas-ligand and other members of the TNF family. Mol. Immunol. 1995; 32: 761-772.
46. Smith CA, Davis T, Wignall JM et al. T2 Open reading frame from the shope fibroma virus encodes a soluble form of the TNF receptor. Biochem. Biophys. Res. Comm. 1991; 176: 335-42.
47. Schreiber M, McFadden G. The Myxoma virus TNF-receptor homologue (T2) inhibits tumor necrosis factor-α in a species specific fashion. Virology 1994; 204: 692-705.
48. Schreiber M, Rajarathnam K, McFadden G. Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homlogue, is secreted as a monomer and dimer that each bind rabbit TNFα, but the dimer is a more potent TNF inhibitor. J. Biol. Chem. 1996; 271: 13 333-41.
49. Shall TJ, Lewis M, Koller KJ et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990; 61: 361-70.
50. Goodwin RG, Anderson D, Jerzy R et al. Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor. Mol. Cell. Biol. 1991; 11: 3020-6.
51. Mohler K, Torrance D, Smith CA et. al. Soluble tumor necrosis factor receptors are effective therapeutic agents in lethal endotoxemia and function simultaneouly as both TNF carriers and TNF antagonists. J. Immunol. 1993; 151: 1548-61.
52. Carswell EA, Old LJ, Kassel RL et al. An endotoxin-inducing serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 1975; 72: 3666-70.
53. Grangee GA, Yamamoto R, Gatanaga T et al. Lymphotoxin, macrophage toxins, tumor necrosis factor and cachectin. In: Osawa T, Bonavida B. (eds) Tumor Necrosis Factor: Structure-Function Relationships and Clinical Application. Basel: Karger, 1992; 25-33.
54. Aggarwal BB, Natarajan K. Tumor necrosis factors: Developments during the last decade. Eur. Cytokine Network 1996; 7: 93-124.
55. Black R, Rauch C, Kozlosky C et al. Cloning of a membrane-bund TNFa converting enzyme (TACE). Eur. Cytokine Network 1996; 7: 210.
56. Moss M, Jin C, Becherer D et al. Structural features and biochemical properties of TNF-alpha convertase. Eur. Cytokine Network 1996; 7: 181.
57. Jones EY, Stuart DI, Walker NPC. Structure of tumour necrosis factor. Nature 1989; 338: 225-8.
58. Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.
59. Vassalli P. The pathophysiology of tumor necrosis factors. Ann. Rev. Immunol. 1992; 10: 411-52.
60. Mestan J, Digel W, Mittnacht S et al. Antiviral effects of recombinant tumour necrosis factor in vitro. Nature 1986; 235: 816-19.
61. Wong GHW, Goeddel DV. Tumour necrosis factors a and β inhibit virus replication and synergise with interferons. Nature 1986; 323: 819-22.
62. Sambhi SK, Kohonen-Coris MRJ, Ramshaw IA. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc. Natl Acad. Sci. USA 1991; 88: 4025-9.
63. Rossol-Voth RS, Rossol S, Schutt KH et al. In vivo protective effect of tumour necrosis factor-α against experimental infection with herpes simplex virus type 1. J. Gen. Virol. 1991; 72: 143-7.
64. Ramshaw IA, Ruby J, Ramsay A, Ada G, Kurapiah G. Expression of cytokines by vaccinia viruses: A model for studying cytokines in virus infections in vivo. Immunol. Rev. 1992; 127: 157-82.
65. Myers K, Marshall ID, Fenner F. Studies in the epidemiology of infectious myxomatosis of rabbits. III. Observations on two succeeding epizootics in Australian wild rabbits on the Riverine plain of south-eastern Australia. J. Hyg. 1954; 52: 337-40.
66. Marshall ID, Fenner F. Studies in the epidemiology of infectious myxomatosis of rabbits. IV. Changes in the innate resistance of Australian wild rabbits exposed to Myxomatosis. J. Hyg. 1958; 56: 288-94.
67. Fenner F, Ratcliffe FN. Myxomatosis. Cambridge: Cambridge University Press, 1965.
68. Fenner F, Myers K. Myxoma virus and myxomatosis in retrospect: The first quarter century of a new disease. In: Kurstock E, Maramorosch K (eds) Viruses and Environment. New York: Academic Press, 1978; 539-70.
69. Schreiber M, McFadden G. Mutational analysis of the ligand binding domain of MT-2 protien, the TNF receptor homologue of myxoma virus. J. Immunol. (in press).
70. Strayer DS, Poxviruses. In: Specter S, Bendelli M, Friedman H, eds. Virus Immunosuppression. New York: Plenum Press, 1988; 173-92.
71. McFadden G. Rabbit, hare, squirrel and swine poxviruses In: Webster R, Granoff A, eds. Encyclopedia of Virology. San Diego: Academic Press, 1994; 1153-60.
72. Macen JL, Graham K, Lee SF et al. Expression of the Myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes. Virology 1996; 218: 232-7.
73. Vandenabeele P, Declercq W, Beyaert R, Friers W. Two tumour necrosis factor receptors: Structure and function. Trends Cell Biol. 1995; 5: 392-9.
74. Fisher GH, Rosenberg FJ, Strauss SE et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935-46.
75. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternate splicing. J. Immunol. 1995; 154: 2706-13.
76. Cascina I, Papoff G, De Maria R, Testi R, Ruberti G. Fas/ Apo-1 (CD95) receptor lacking the intracytoplasmic signalling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol. 1996; 156: 13-17.
77. Gooding LR. Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect. Agents Dis. 1994; 3: 106-15.